Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 14;59(9):1661.
doi: 10.3390/medicina59091661.

Insights into Microbiota in Sjögren's Syndrome

Diana Mieliauskaitė  1 , Vilius Kontenis  1
Affiliations
Review

Insights into Microbiota in Sjögren's Syndrome

Diana Mieliauskaitė et al. Medicina (Kaunas). .

Abstract

Primary Sjögren's syndrome (pSS) is a heterogeneous chronic autoimmune disorder with multiple clinical manifestations that can develop into non-Hodgkin's lymphoma in mucosa-associated lymphoid tissue. The pathogenesis of Sjögren's syndrome (SS) is not completely understood, but it is assumed that pathogenesis of SS is multifactorial. The microbiota plays a notable role in the development of autoimmune disorders, including Sjögren's syndrome. Molecular mimicry, metabolite changes and epithelial tolerance breakdown are pathways that might help to clarify the potential contribution of the microbiota to SS pathogenesis. This review aims to provide an overview of recent studies describing microbiota changes and microbiota mechanisms associated with Sjögren's syndrome. Data on the microbiota in SS from PubMed, Web of Science, Scopus and the Cochrane Library databases are summarized. Overall, the microbiota makes a major contribution to the development of Sjögren's syndrome and progression. Future microbiota studies should improve the management of this heterogeneous autoimmune disease.

Keywords: Sjögren’s syndrome; autoimmune diseases; dysbiosis; epithelial tolerance; metabolite; microbiota; molecular mimicry.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Driving factors of microbiota dysbiosis (Huang, X.; et al., 2023) [22].
Figure 2
Figure 2
Potential role of microbiota in SS pathogenesis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Manfrè: V., Chatzis L.G., Cafaro G., Fonzetti S.S., Calvacchi S., Fulvio G., Navarro Garcia I.C., La Rocca G., Ferro F., Perricone C., et al. Sjögren’s syndrome: One year in review 2022. Clin. Exp. Rheumatol. 2022;40:2211–2224. doi: 10.55563/clinexprheumatol/43z8gu. - DOI - PubMed
    1. Shimizu T., Nakamura H., Kawakami A. Role of the innate immunity signaling pathway in the pathogenesis of Sjogren’s syndrome. Int. J. Mol. Sci. 2021;22:3090. doi: 10.3390/ijms22063090. - DOI - PMC - PubMed
    1. Chivasso C., Sarrand J., Perret J., Delporte C., Soyfoo M.S. The involvement of innate and adaptive immunity in the initiation and perpetuation of Sjogren’s syndrome. Int. J. Mol. Sci. 2021;22:658. doi: 10.3390/ijms22020658. - DOI - PMC - PubMed
    1. Verstappen G.M., Pringle S., Bootsma H., Kroese F.G.M. Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Nat. Rev. Rheumatol. 2021;17:333–348. doi: 10.1038/s41584-021-00605-2. - DOI - PMC - PubMed
    1. Deng C., Xiao Q., Fei Y. A Glimpse Into the Microbiome of Sjögren’s Syndrome. Front. Immunol. 2022;13:918619. doi: 10.3389/fimmu.2022.918619. - DOI - PMC - PubMed